MAPK3 and colonic neoplasm: Trametinib inhibited phosphorylated ERK1/2 (P-ERK1/2) in K-Ras mutant colon cancer cell lines HCT116 (G13D), LS174T (G12D) and DLD-1 (G13D) (Figure 2).